On October 21, 2013, Depomed, Inc. (DEPO) announced that it has sold its interests in royalty and milestone payments under its license agreements in the Type 2 diabetes therapeutic area to PDL BioPharma (PDLI), Inc. for $240.5 million in cash. The interests sold include royalty and milestone payments accruing from and after October 1, 2013:
1) From Santarus (SNTS) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the U.S.
- Santarus has been doing an incredible job selling Glumetza over the past few years. Glumetza contributed $14.2 million in royalties in the second quarter 2013 on of sales at Santarus of $44.4 million. Total Glumetza royalties in 2012 were $42.7 million; which
Only subscribers can access this article, which is part of the PRO research library covering 3,582 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: